Ocean Biomedical announced that the United States Patent and Trademark Office has issued a patent covering Ocean’s anti-Chitinase 1 small molecule candidate. Dr. Jack A. Elias, MD, one of Ocean’s Scientific Co-founders, discovered this molecule to be a key factor in controlling and inhibiting fibrosis progression, with potential application in several major fibrotic diseases. Targeted diseases include alcoholic liver disease, idiopathic pulmonary fibrosis, scleroderma, nonalcoholic steatohepatitis, and Hermansky-Pudlak Syndrome. Ocean Biomedical is the exclusive licensee of this patent family. The patent is U.S. Patent No. 11,717,528 B2, titled “Methods and Compositions Relating to the Treatment of Fibrosis.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OCEA:
- Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S.
- Ocean Biomedical provides latest updates on its broad programs
- Ocean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple Cancers
- Ocean Biomedical (NASDAQ: OCEA) Share Price Target Now Averaging $18.21, Based on Research and Development Progress in Three Promising Programs Generating Novel Treatment Candidates for Cancer, Malaria, and Fibrosis.
- Ocean Biomedical shares details of its Lung Cancer Program